Publications by authors named "Jennifer Libous"

Claim this Profile
I
Infectivity and Immunogenicity of Live-Attenuated Respiratory Syncytial Virus Vaccines in Human Immunodeficiency Virus-Exposed Uninfected Children.
Matthew S Kelly, Coleen K Cunningham, Elizabeth J McFarland, Mark J Giganti, Jane C Lindsey, Jennifer L Libous

Open Forum Infect Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children.
Coleen K Cunningham, Ruth A Karron, Petronella Muresan, Matthew S Kelly, Elizabeth J McFarland, Jennifer Libous

J Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
Mina Nikanjam, Lana Tran, Ellen G Chadwick, Mutsa Bwakura-Dangarembizi, Carolyn Bolton Moore, Jennifer Libous

AIDS· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMPAACT 2016: Operationalizing HIV Intervention Adaptations to Inform the Science and Outcomes of Implementation.
Jennifer L Libous, Nicole A Montañez, Dorothy E Dow, Suad Kapetanovic, Janice Buckley

Front Reprod Health· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.
Ruth A Karron, Jessica E Atwell, Elizabeth J McFarland, Coleen K Cunningham, Petronella Muresan, Jennifer Libous

Am J Respir Crit Care Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children.
Elizabeth J McFarland, Ruth A Karron, Petronella Muresan, Coleen K Cunningham, Charlotte Perlowski, Jennifer Libous

J Infect Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.
Elizabeth J McFarland, Ruth A Karron, Petronella Muresan, Coleen K Cunningham, Jennifer Libous

J Infect Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
Mutsa Bwakura Dangarembizi, Pearl Samson, Edmund V Capparelli, Carolyn Bolton Moore, Patrick Jean-Philippe, Jennifer L Libous

J Acquir Immune Defic Syndr· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated.
Coleen K Cunningham, Ruth Karron, Petronella Muresan, Elizabeth J McFarland, Charlotte Perlowski, Jennifer Libous

Open Forum Infect Dis· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis